Status:
UNKNOWN
Oxaliplatin-induced Portal Hypertension
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Gastroesophageal Varices Hemorrhage
Colorectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxic...
Eligibility Criteria
Inclusion
- Sign written informed consent
- Male or female patients aged 18-75
- diagnosed as portal hypertension by contrast-enhanced computed tomography
- and confirmed gastroesophageal varices by upper digestive endoscopy;
- had a history of oxaliplatin-based chemotherapy after colorectal cancer surgery;
Exclusion
- combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.
- with colorectal cancer required further anti-tumor treatment
- Other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.
Key Trial Info
Start Date :
August 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04524676
Start Date
August 31 2020
End Date
September 30 2022
Last Update
August 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology and Hepatology
Shanghai, Shanghai Municipality, China, 200032